these four are signficant players in the genome sequencing market, but RHHB stock price hasn't take off in the same way, and Agilent is way out in front.
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。